^
Contact us  to learn more about
our Premium Content:  News alerts, weekly reports and conference planners
GENE:

IRAK4 (Interleukin 1 Receptor Associated Kinase 4)

i
Other names: IRAK4, Interleukin 1 Receptor Associated Kinase 4, Interleukin-1 Receptor-Associated Kinase 4, Renal Carcinoma Antigen NY-REN-64, NY-REN-64, IRAK-4, IMD67, REN64, IPD1
Associations
3d
Salvia coccinea and Apigenin: A Natural Treasure of Lamiaceae in Pharmacological Innovation. (PubMed, Food Sci Nutr)
Furthermore, apigenin and Salvia coccinea promote hypoglycemic effect by attenuating α-amylase activity, cholesterol levels, insulin resistance, DRP1 expression by improving GLUT4, GSK-3β, AMPK/PI3K/Nrf2, and Akt pathways. Moreover, Salvia coccinea regulates wound healing after infection, injury, or surgery, in addition to improving agricultural productivity by reducing rodent attacks.
Review • Journal • PARP Biomarker • IO biomarker
|
BCL2 (B-cell CLL/lymphoma 2) • JAK2 (Janus kinase 2) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • STAT3 (Signal Transducer And Activator Of Transcription 3) • BAX (BCL2-associated X protein) • CASP3 (Caspase 3) • TGFB1 (Transforming Growth Factor Beta 1) • TLR4 (Toll Like Receptor 4) • CDK1 (Cyclin-dependent kinase 1) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4) • SLC2A4 (Solute Carrier Family 2 Member 4)
4d
Discovery of Novel, Potent, and Selective IRAK1 Inhibitors as Potential Therapeutics for Hepatocellular Carcinoma. (PubMed, J Med Chem)
A34 potently inhibited IRAK1 with an IC50 value of 10.6 nM and demonstrated exceptional selectivity over 215 other kinases, notably including IRAK4. Furthermore, A34 demonstrated significant anti-HCC activity both in vivo and in vitro, making it a valuable chemical probe for IRAK1 and a potential lead candidate for the treatment of HCC.
Journal
|
IL1R1 (Interleukin 1 receptor, type I) • IRAK1 (Interleukin 1 Receptor Associated Kinase 1) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
9d
Peptide OH-CATH30 Mitigates Cachexia-Induced Muscle Atrophy via Modulation of TLR4-Associated Inflammation. (PubMed, J Cachexia Sarcopenia Muscle)
Our findings underscore the critical role of TLR4 signalling in cachexia-associated muscle wasting across different disease contexts and demonstrate the efficacy of OH-CATH30, a TLR4 inhibitor, in alleviating muscle atrophy in various cachexia models.
Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • CD14 (CD14 Molecule) • TLR4 (Toll Like Receptor 4) • FBXO32 (F-Box Protein 32) • GABARAPL1 (GABA Type A Receptor Associated Protein Like 1) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
|
cisplatin
11d
Synthesis and in vitro characterization of novel IRAK-4 inhibitor compounds. (PubMed, Prep Biochem Biotechnol)
In silico ADME predictions indicated promising pharmacokinetic properties, including good intestinal absorption and blood-brain barrier penetration. Overall, the study confirms that all four compounds as strong IRAK-4 inhibitors, with IGYZT01058 standing out as the most potent, suggesting its potential as a therapeutic agent for autoimmune diseases and sepsis.
Preclinical • Journal
|
IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
12d
IRAK4 Regulates NF-κB signaling to suppress CD8 + T cell activity and promote immune evasion in glioblastoma development. (PubMed, Cancer Immunol Immunother)
These findings highlight IRAK4 as a key regulator of NF-κB-mediated immune evasion in glioblastoma, suggesting its potential as a therapeutic target to enhance CD8+ T cell-based immunotherapy. This study provides novel insights into glioblastoma's immune regulatory mechanisms and supports the development of targeted immunotherapies.
Journal • IO biomarker
|
CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • TNFA (Tumor Necrosis Factor-Alpha) • NFKBIA (NFKB Inhibitor Alpha 2) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
19d
Rapid flow cytometric diagnosis of XIAP deficiency. (PubMed, Pediatr Allergy Immunol)
In XIAP deficiency, MDP-flow CD62L enabled faster functional analysis than MDP-flow TNF-α. These analyses are also useful for post-HCT functional assessment.
Journal
|
TNFA (Tumor Necrosis Factor-Alpha) • XIAP (X-Linked Inhibitor Of Apoptosis) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4) • SELL (Selectin L)
20d
The Molecular Mechanism of Silymarin in Relieving Myocardial Fibrosis and Reducing Oxidative Stress Levels in Adjuvant-Induced Rheumatoid Arthritis Rats by Inhibiting IRAK4. (PubMed, J Biochem Mol Toxicol)
Rats were randomly divided into five groups: healthy control (Control), untreated RA model (Model), SIL (25 mg/kg/day), SIL (50 mg/kg/day), and methotrexate (7.6 mg/kg/day) groups, with 10 mice in each group...SIL effectively mitigates myocardial fibrosis and oxidative stress in adjuvant-induced RA rats, primarily through inhibition of IRAK4-mediated inflammatory signaling. These findings highlight SIL as a promising therapeutic candidate for RA-related cardiac injury.
Preclinical • Journal • IO biomarker
|
IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • BAX (BCL2-associated X protein) • IL1B (Interleukin 1, beta) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
|
methotrexate
2ms
Toll-like Receptors in Inborn Errors of Immunity in Children: Diagnostic Potential and Therapeutic Frontiers-A Review of the Latest Data. (PubMed, Cells)
Despite significant progress, substantial knowledge gaps remain, particularly regarding the full spectrum of TLR signaling abnormalities across IEI subtypes. The conclusions emphasize the need for large-scale, international studies to achieve a comprehensive understanding of pathogenic mechanisms and to develop more targeted and effective therapeutic interventions for children affected by these rare disorders.
Review • Journal • IO biomarker
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • TLR3 (Toll Like Receptor 3) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
3ms
PSP-0119: Targeted IRAK4 Degradation as a Novel Therapeutic Strategy for FLT3-Mutant AML. (PubMed, bioRxiv)
PSP-0119 is metabolically stable, retaining 71% of parent compound at 60 minutes in human liver microsomes. In summary, IRAK4 degradation via PSP-0119 as a promising therapeutic strategy for treatment of FLT3-mutant AML.
Journal
|
FLT3 (Fms-related tyrosine kinase 3) • CRBN (Cereblon) • IL1B (Interleukin 1, beta) • NOS3 (Nitric oxide synthase 3) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
|
FLT3-ITD mutation • FLT3 mutation • Chr t(15;17)
3ms
Clinical features and functional validation of IRAK4 gene deficiency (PubMed, Zhonghua Er Ke Za Zhi)
IRAK4 deficiency should be suspected in patients with early-onset recurrent bacterial infections and attenuated inflammatory response. Homozygous and compound heterozygous frameshift variants in IRAK4 gene lead to truncated IRAK4 proteins and impared innate immune signaling.
Journal • IO biomarker
|
IFNG (Interferon, gamma) • IL6 (Interleukin 6) • TNFA (Tumor Necrosis Factor-Alpha) • TLR4 (Toll Like Receptor 4) • IL17A (Interleukin 17A) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
4ms
Pathological insights and molecular responses to Morganella morganii infection in largemouth bass (Micropterus salmoides). (PubMed, Dev Comp Immunol)
Antibiotic susceptibility testing indicated clinical potential for enrofloxacin and ciprofloxacin treatment, though resistance to azithromycin was observed. These findings demonstrate M. morganii's significant threat to bass aquaculture through metabolic disruption and immune function, meanwhile identifying potential treatment options.
Journal
|
MYD88 (MYD88 Innate Immune Signal Transduction Adaptor) • IL10 (Interleukin 10) • IRAK4 (Interleukin 1 Receptor Associated Kinase 4)
5ms
Generation of a potent & selective series of IRAK4 inhibitors based on a structure based, hybridization approach. (PubMed, Bioorg Med Chem)
In this article, we describe the development of a highly potent and selective IRAK4 lead compound 5e, starting from Astellas AS2444697 (1a). The work includes identification of the pyrazole-pyridine substituent in compound 1g, binding towards the gatekeeper region of IRAK4, followed by a structure-guided scaffold hybridization that led to 5a. Subsequent optimization of substituents of the indazole scaffold yielded 5e, which exhibits a 10-fold improvement in IRAK4 cell potency and higher off-target selectivity compared to AS244697 (1a).
Journal
|
IRAK4 (Interleukin 1 Receptor Associated Kinase 4)